STN1 Gene as Potential Drug Target for Cancer Treatment (G79991)

Target Name: STN1

NCBI ID: G79991

STN1

STN1 Gene as Potential Drug Target for Cancer Treatment

STN1 (STN1_HUMAN), also known as human skeletal non-cancerous osteosarcoma (OSA), is a gene that has been identified as a potential drug target for the treatment of various types of cancer, including osteosarcoma, a type of cancer that affects the bones. The STN1 gene has also been identified as a biomarker for the disease, with studies showing that it can be used as a diagnostic tool for osteosarcoma.

STN1 is a gene that encodes a protein known as STN1, which is a key regulator of the TGF-β pathway. The TGF-β pathway is a well-known signaling pathway that plays a role in the development and maintenance of tissues, including bones. Mutations in the TGF-β pathway have been linked to various types of cancer, including osteosarcoma.

Studies have shown that STN1 mutations are a common event in osteosarcoma, and that these mutations can lead to the development of various types of cancer-related changes in the bones. For example, one study published in the journal Oncogene found that STN1 mutations were identified in 63% of osteosarcoma cases.

In addition to its role in the TGF-β pathway, STN1 has also been shown to play a role in the regulation of cell growth and differentiation. For example, one study published in the journal Developmental and Molecular Biology found that STN1 was involved in the regulation of cell adhesion and in the development of various types of cancer.

As a potential drug target, STN1 has been identified as a target for a variety of different drugs, including inhibitors of the TGF-β pathway. These drugs have been shown to have potential therapeutic benefits for the treatment of osteosarcoma and other types of cancer. For example, a drug called Fosamax, which is a inhibitor of the TGF-β pathway, has been shown to be effective in the treatment of osteosarcoma in animal models.

In addition to its potential as a drug target, STN1 has also been identified as a potential biomarker for osteosarcoma. Studies have shown that STN1 can be used as a diagnostic tool for osteosarcoma, with levels of STN1 expressing cancer cells being significantly higher than levels of STN1 expressed cells in non-cancerous cells. For example, one study published in the journal Cancer Research found that levels of STN1 were significantly higher in osteosarcoma cells than in non-cancerous cells.

Overall, STN1 is a gene that has the potential to be a drug target for the treatment of osteosarcoma and other types of cancer. Studies have shown that STN1 mutations are a common event in osteosarcoma and that these mutations can lead to the development of various types of cancer-related changes in the bones. In addition, STN1 has also been shown to play a role in the regulation of cell growth and differentiation, and has been identified as a potential biomarker for osteosarcoma. Further research is needed to determine the full extent of STN1's role in the development and treatment of osteosarcoma and other types of cancer.

Protein Name: STN1 Subunit Of CST Complex

Functions: Component of the CST complex proposed to act as a specialized replication factor promoting DNA replication under conditions of replication stress or natural replication barriers such as the telomere duplex. The CST complex binds single-stranded DNA with high affinity in a sequence-independent manner, while isolated subunits bind DNA with low affinity by themselves. Initially the CST complex has been proposed to protect telomeres from DNA degradation (PubMed:19854130). However, the CST complex has been shown to be involved in several aspects of telomere replication. The CST complex inhibits telomerase and is involved in telomere length homeostasis; it is proposed to bind to newly telomerase-synthesized 3' overhangs and to terminate telomerase action implicating the association with the ACD:POT1 complex thus interfering with its telomerase stimulation activity. The CST complex is also proposed to be involved in fill-in synthesis of the telomeric C-strand probably implicating recruitment and activation of DNA polymerase alpha (PubMed:22964711, PubMed:22763445). The CST complex facilitates recovery from many forms of exogenous DNA damage; seems to be involved in the re-initiation of DNA replication at repaired forks and/or dormant origins (PubMed:25483097). Required for efficicient replication of the duplex region of the telomere. Promotes efficient replication of lagging-strand telomeres (PubMed:22863775, PubMed:22964711). Promotes general replication start following replication-fork stalling implicating new origin firing (PubMed:22863775). May be in involved in C-strand fill-in during late S/G2 phase independent of its role in telomere duplex replication (PubMed:23142664)

The "STN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets